ANIX - NASDAQ
Anixa Biosciences, Inc.
$2.52
-6.7%Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell technology, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer; and the discovery and development of anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain protein functions of the virus. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. It has a collaboration agreement with MolGenie GmbH to discover and develop anti-viral drug candidates against COVID-19. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.
At a Glance
Live SnapshotAnixa Biosciences, Inc. Profit Bridge
Profitability Analysis
Anixa Biosciences, Inc. Income Statement
ANIX • NASDAQ
| Anixa Biosciences, Inc. Income Statement | Oct 2025 | Oct 2024 | Oct 2023 | Oct 2022 | Oct 2021 | Oct 2020 | Oct 2019 | Oct 2018 | Oct 2017 | Oct 2016 | Oct 2015 | Oct 2014 | Oct 2013 | Oct 2012 | Oct 2011 | Oct 2010 | Oct 2009 | Oct 2008 | Oct 2007 | Oct 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
REVENUE | ||||||||||||||||||||
0.0 | 0.0 | 210K | 0.0 | 512K | 0.0 | 250K | 1.1M | 362.5K | 300K | 9.3M | 3.7M | 388.9K | 940K | 1M | 730.7K | 1.1M | 2.1M | 486.9K | 508.7K | |
GROSS PROFIT | ||||||||||||||||||||
(36K) | (0.0) | (161K) | (0.0) | (385K) | (90.2K) | (166.3K) | (768.4K) | (104.6K) | (217.4K) | (3.6M) | (2M) | (316.7K) | (3.9K) | (34.1K) | (82.3K) | (65.7K) | (95.6K) | (160.4K) | (156.4K) | |
-36K | 0.0 | 49K | 0.0 | 127K | -90.2K | 83.8K | 344.1K | 257.9K | 82.6K | 5.6M | 1.7M | 72.2K | 936.1K | 969.1K | 648.4K | 990.1K | 2M | 326.5K | 352.2K | |
OPERATING INCOME | ||||||||||||||||||||
(11.7M) | (13.8M) | (11.1M) | (13.9M) | (13.3M) | (9.9M) | (11.6M) | (14.1M) | (6.3M) | (4.6M) | (6.6M) | (6.7M) | (8M) | (5.1M) | (6M) | (5.9M) | (8.3M) | (8M) | (5.5M) | (8M) | |
(6.6M) | (7.4M) | (6.3M) | (7.2M) | (7.1M) | (5.5M) | (5.7M) | (6.9M) | (4.4M) | (2.7M) | (5.5M) | (6.4M) | (8M) | (2.9M) | (2.9M) | (2.9M) | (4.2M) | (3.8M) | (2.4M) | (3.4M) | |
(5.1M) | (6.4M) | (4.8M) | (6.7M) | (6.2M) | (4.4M) | (5.5M) | (6.8M) | (1.6M) | (1.6M) | (711.4K) | (1.2M) | (0.0) | (2.2M) | (3.1M) | (3M) | (4.1M) | (4.1M) | (3.4M) | (4.6M) | |
-11.7M | -13.8M | -11M | -13.9M | -13.1M | -10M | -11.5M | -14.3M | -6.1M | -4.5M | -944.8K | -5M | -7.9M | -4.1M | -5M | -5.2M | -7.3M | -6M | -5.5M | -7.6M | |
PRE-TAX INCOME | ||||||||||||||||||||
(0.0) | (0.0) | (0.0) | (104K) | (322.0) | (0.0) | (0.0) | (0.0) | (500.5K) | (519.9K) | (451.9K) | (1.3M) | (1.1M) | (7.7K) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
673K | 1.1M | 1.1M | 0.0 | 2K | 33.9K | 71.4K | 46K | -481K | -507.4K | -434.3K | -1.3M | -1.1M | -4.2K | 2.5K | 4.9K | 20.8K | 37K | 0.0 | 0.0 | |
-36K | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (418.8K) | (0.0) | -13.1K | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (47.5K) | (0.0) | (0.0) | (0.0) | |
673K | 1.1M | 1.1M | 104K | 7.8K | -114.2K | 71.4K | 46K | 1.1M | -507.4K | -434.3K | -4.6M | -2.2M | -118.2K | -1.7M | 73.1K | -9.2M | 167.9K | 34.1K | 26.7K | |
-11M | -12.7M | -9.9M | -13.8M | -13.1M | -10.1M | -11.8M | -14.2M | -5M | -5M | -1.4M | -9.6M | -10.1M | -4.3M | -6.8M | -5.2M | -16.5M | -5.8M | 0.0 | 0.0 | |
NET INCOME | ||||||||||||||||||||
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (175.8K) | (0.0) | (0.0) | (12.5K) | (0.0) | (0.0) | (0.0) | (430.0) | (600K) | (0.0) | (0.0) | (0.0) | (259.7K) | -26.7K | |
-10.9M | -12.6M | -9.8M | -13.6M | -12.9M | -10.1M | -12M | -14M | -5M | -5M | -1.4M | -9.6M | -10.1M | -4.3M | -7.4M | -5.2M | -16.5M | -5.8M | -5.5M | -7.6M |
SEC Filings
ANIX - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | March 11, 2026 | March 10, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | March 09, 2026 | January 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | February 09, 2026 | February 09, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | January 28, 2026 | January 28, 2026 | 2026 | |
10-K 10-K 2025 FY FY | January 12, 2026 | October 31, 2025 | 2025 | |
8-K 8-K 2025 N/A | December 12, 2025 | December 11, 2025 | 2025 | |
10-Q 10-Q 2025 Q3 Q3 | September 10, 2025 | July 31, 2025 | 2025 | |
S-3 S-3 N/A | September 10, 2025 | September 10, 2025 | ||
10-Q 10-Q 2025 Q2 Q2 | May 28, 2025 | April 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | March 21, 2025 | March 20, 2025 | 2025 |
Related Guides
Continue your ANIX research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.